Skip to main content
Premium Trial:

Request an Annual Quote

Bioinformatics Analysis Homes in on Two Dozen Genes That Could Be Targets for Drugs in Obesity

In a bioinformatic analysis, researchers have identified nearly two dozen genes implicated in obesity that could be targeted by 78 approved and marketed drugs, in a new Journal of Human Genetics study. A team from the National Center for Global Health and Medicine in Tokyo compiled a list of nearly 29,000 SNPs that have been linked to obesity through a genome-wide association study and used bioinformatic databases and tools to prioritize 1,372 genes associated with these SNPs with supporting eQTL data, tissue or cell data, or transcriptomic data. After a subsequent protein network analysis, they further focused in on 74 key obesity genes, and, of these, 23 are targets for 78 US Food and Drug Administration-approved drugs, suggesting that some of these drugs could be repurposed to treat obesity. "Supplementing our findings with empirical experiments would improve our comprehension of regulatory gene interactions and their role in obesity, bringing us closer to effective obesity treatment," the researchers write.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.